Other Barks & Bites for Friday, May 21: Congress Attacks AbbVie’s Humira Patent Practices, SCOTUS Denies Cert in Enbrel Patent Case and Germany’s Bundestag Passes Controversial ‘Minor Use’ Copyright Provision

This week in Other Barks & Bites: the House Oversight Committee takes action against AbbVie’s patent practices regarding its blockbuster drug Humira; TSMC increases microcontroller output by 60% to address the global chip shortage; the Ninth Circuit affirms that USPTO communications with patent applicants are not information collections under the Paperwork Reduction Act; the U.S. Supreme Court denies cert to a Sandoz appeal on issues of double patenting involving the autoimmune disorder treatment Enbrel; Germany’s federal parliament passed a bill implementing the EU Copyright Directive including a controversial “minor use” provision; China joins the EUIPO’s TMview database; the USPTO issues proposed rules to implement the Trademark Modernization Act; and the USITC institutes a Section 337 patent infringement investigation against Apple’s wearable ECG devices.

Full Article Available Here